1
|
Zhang S, Staples AE. Microfluidic-based systems for the management of diabetes. Drug Deliv Transl Res 2024:10.1007/s13346-024-01569-y. [PMID: 38509342 DOI: 10.1007/s13346-024-01569-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2024] [Indexed: 03/22/2024]
Abstract
Diabetes currently affects approximately 500 million people worldwide and is one of the most common causes of mortality in the United States. To diagnose and monitor diabetes, finger-prick blood glucose testing has long been used as the clinical gold standard. For diabetes treatment, insulin is typically delivered subcutaneously through cannula-based syringes, pens, or pumps in almost all type 1 diabetic (T1D) patients and some type 2 diabetic (T2D) patients. These painful, invasive approaches can cause non-adherence to glucose testing and insulin therapy. To address these problems, researchers have developed miniaturized blood glucose testing devices as well as microfluidic platforms for non-invasive glucose testing through other body fluids. In addition, glycated hemoglobin (HbA1c), insulin levels, and cellular biomechanics-related metrics have also been considered for microfluidic-based diabetes diagnosis. For the treatment of diabetes, insulin has been delivered transdermally through microdevices, mostly through microneedle array-based, minimally invasive injections. Researchers have also developed microfluidic platforms for oral, intraperitoneal, and inhalation-based delivery of insulin. For T2D patients, metformin, glucagon-like peptide 1 (GLP-1), and GLP-1 receptor agonists have also been delivered using microfluidic technologies. Thus far, clinical studies have been widely performed on microfluidic-based diabetes monitoring, especially glucose sensing, yet technologies for the delivery of insulin and other drugs to diabetic patients with microfluidics are still mostly in the preclinical stage. This article provides a concise review of the role of microfluidic devices in the diagnosis and monitoring of diabetes, as well as the delivery of pharmaceuticals to treat diabetes using microfluidic technologies in the recent literature.
Collapse
Affiliation(s)
- Shuyu Zhang
- Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Blacksburg, VA, 24061, USA.
- Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, 24061, USA.
| | - Anne E Staples
- Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Blacksburg, VA, 24061, USA
- Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA, 24061, USA
| |
Collapse
|
2
|
Regeenes R, Rocheleau JV. Twenty years of islet-on-a-chip: microfluidic tools for dissecting islet metabolism and function. LAB ON A CHIP 2024; 24:1327-1350. [PMID: 38277011 DOI: 10.1039/d3lc00696d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2024]
Abstract
Pancreatic islets are metabolically active micron-sized tissues responsible for controlling blood glucose through the secretion of insulin and glucagon. A loss of functional islet mass results in type 1 and 2 diabetes. Islet-on-a-chip devices are powerful microfluidic tools used to trap and study living ex vivo human and murine pancreatic islets and potentially stem cell-derived islet organoids. Devices developed over the past twenty years offer the ability to treat islets with controlled and dynamic microenvironments to mimic in vivo conditions and facilitate diabetes research. In this review, we explore the various islet-on-a-chip devices used to immobilize islets, regulate the microenvironment, and dynamically detect islet metabolism and insulin secretion. We first describe and assess the various methods used to immobilize islets including chambers, dam-walls, and hydrodynamic traps. We subsequently describe the surrounding methods used to create glucose gradients, enhance the reaggregation of dispersed islets, and control the microenvironment of stem cell-derived islet organoids. We focus on the various methods used to measure insulin secretion including capillary electrophoresis, droplet microfluidics, off-chip ELISAs, and on-chip fluorescence anisotropy immunoassays. Additionally, we delve into the various multiparametric readouts (NAD(P)H, Ca2+-activity, and O2-consumption rate) achieved primarily by adopting a microscopy-compatible optical window into the devices. By critical assessment of these advancements, we aim to inspire the development of new devices by the microfluidics community and accelerate the adoption of islet-on-a-chip devices by the wider diabetes research and clinical communities.
Collapse
Affiliation(s)
- Romario Regeenes
- Advanced Diagnostics, Toronto General Hospital Research Institute, Toronto, ON, Canada
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada
| | - Jonathan V Rocheleau
- Advanced Diagnostics, Toronto General Hospital Research Institute, Toronto, ON, Canada
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- Departments of Medicine and Physiology, University of Toronto, ON, Canada
| |
Collapse
|
3
|
Quintard C, Tubbs E, Jonsson G, Jiao J, Wang J, Werschler N, Laporte C, Pitaval A, Bah TS, Pomeranz G, Bissardon C, Kaal J, Leopoldi A, Long DA, Blandin P, Achard JL, Battail C, Hagelkruys A, Navarro F, Fouillet Y, Penninger JM, Gidrol X. A microfluidic platform integrating functional vascularized organoids-on-chip. Nat Commun 2024; 15:1452. [PMID: 38365780 PMCID: PMC10873332 DOI: 10.1038/s41467-024-45710-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 02/02/2024] [Indexed: 02/18/2024] Open
Abstract
The development of vascular networks in microfluidic chips is crucial for the long-term culture of three-dimensional cell aggregates such as spheroids, organoids, tumoroids, or tissue explants. Despite rapid advancement in microvascular network systems and organoid technologies, vascularizing organoids-on-chips remains a challenge in tissue engineering. Most existing microfluidic devices poorly reflect the complexity of in vivo flows and require complex technical set-ups. Considering these constraints, we develop a platform to establish and monitor the formation of endothelial networks around mesenchymal and pancreatic islet spheroids, as well as blood vessel organoids generated from pluripotent stem cells, cultured for up to 30 days on-chip. We show that these networks establish functional connections with the endothelium-rich spheroids and vascular organoids, as they successfully provide intravascular perfusion to these structures. We find that organoid growth, maturation, and function are enhanced when cultured on-chip using our vascularization method. This microphysiological system represents a viable organ-on-chip model to vascularize diverse biological 3D tissues and sets the stage to establish organoid perfusions using advanced microfluidics.
Collapse
Affiliation(s)
- Clément Quintard
- Univ. Grenoble Alpes, CEA, IRIG/BGE, BIOMICS, 38000, Grenoble, France
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia (BC), Canada
| | - Emily Tubbs
- Univ. Grenoble Alpes, CEA, IRIG/BGE, BIOMICS, 38000, Grenoble, France
| | - Gustav Jonsson
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, IMBA, Dr. Bohr-Gasse 3, 1030, Vienna, Austria
- Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, 1030, Vienna, Austria
- Eric Kandel Institute, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - Jie Jiao
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia (BC), Canada
| | - Jun Wang
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia (BC), Canada
| | - Nicolas Werschler
- School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia (BC), Canada
| | - Camille Laporte
- Univ. Grenoble Alpes, CEA, IRIG/BGE, BIOMICS, 38000, Grenoble, France
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
| | - Amandine Pitaval
- Univ. Grenoble Alpes, CEA, IRIG/BGE, BIOMICS, 38000, Grenoble, France
| | - Thierno-Sidy Bah
- Univ. Grenoble Alpes, CEA, IRIG, BGE, Gen&Chem, 38000, Grenoble, France
| | - Gideon Pomeranz
- Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK
| | | | - Joris Kaal
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
| | - Alexandra Leopoldi
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, IMBA, Dr. Bohr-Gasse 3, 1030, Vienna, Austria
- Eric Kandel Institute, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - David A Long
- Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Pierre Blandin
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
| | - Jean-Luc Achard
- Université Grenoble Alpes, CNRS, Grenoble INP, LEGI, 38000, Grenoble, France
| | | | - Astrid Hagelkruys
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, IMBA, Dr. Bohr-Gasse 3, 1030, Vienna, Austria
- Eric Kandel Institute, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
| | - Fabrice Navarro
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
| | - Yves Fouillet
- Univ. Grenoble Alpes, CEA, LETI, DTBS, 38000, Grenoble, France
| | - Josef M Penninger
- Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia (BC), Canada.
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, IMBA, Dr. Bohr-Gasse 3, 1030, Vienna, Austria.
- Eric Kandel Institute, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Helmholtz Centre for Infection Research, Braunschweig, Germany.
| | - Xavier Gidrol
- Univ. Grenoble Alpes, CEA, IRIG/BGE, BIOMICS, 38000, Grenoble, France.
| |
Collapse
|
4
|
Olsen C, Wang C, Aizenshtadt A, Abadpour S, Lundanes E, Skottvoll FS, Golovin A, Busek M, Krauss S, Scholz H, Wilson SR. Simultaneous LC-MS determination of glucose regulatory peptides secreted by stem cell-derived islet organoids. Electrophoresis 2023; 44:1682-1697. [PMID: 37574258 DOI: 10.1002/elps.202300095] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Revised: 07/28/2023] [Accepted: 08/01/2023] [Indexed: 08/15/2023]
Abstract
For studying stem cell-derived islet organoids (SC-islets) in an organ-on-chip (OoC) platform, we have developed a reversed-phase liquid chromatography-tandem mass spectrometry (RPLC-MS/MS) method allowing for simultaneous determination of insulin, somatostatin-14, and glucagon, with improved matrix robustness compared to earlier methodology. Combining phenyl/hexyl-C18 separations using 2.1 mm inner diameter LC columns and triple quadrupole mass spectrometry, identification and quantification were secured with negligible variance in retention time and quantifier/qualifier ratios, negligible levels of carryover (<2%), and sufficient precision (±10% RSD) and accuracy (±15% relative error) with and without use of an internal standard. The obtained lower limits of quantification were 0.2 µg/L for human insulin, 0.1 µg/L for somatostatin-14, and 0.05 µg/L for glucagon. The here-developed RPLC-MS/MS method showed that the SC-islets have an insulin response dependent on glucose concentration, and the SC-islets produce and release somatostatin-14 and glucagon. The RPLC-MS/MS method for these peptide hormones was compatible with an unfiltered offline sample collection from SC-islets cultivated on a pumpless, recirculating OoC (rOoC) platform. The SC-islets background secretion of insulin was not significantly different on the rOoC device compared to a standard cell culture well-plate. Taken together, RPLC-MS/MS method is well suited for multi-hormone measurements of SC-islets on an OoC platform.
Collapse
Affiliation(s)
- Christine Olsen
- Department of Chemistry, University of Oslo, Blindern, Oslo, Norway
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Chencheng Wang
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway
| | - Aleksandra Aizenshtadt
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Shadab Abadpour
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway
| | - Elsa Lundanes
- Department of Chemistry, University of Oslo, Blindern, Oslo, Norway
| | | | - Alexey Golovin
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
| | - Mathias Busek
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Stefan Krauss
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
| | - Hanne Scholz
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway
| | - Steven Ray Wilson
- Hybrid Technology Hub-Centre of Excellence, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
5
|
Adeoye DI, Wang Y, Davis JJ, Roper MG. Automated cellular stimulation with integrated pneumatic valves and fluidic capacitors. Analyst 2023; 148:1227-1234. [PMID: 36786685 PMCID: PMC10023383 DOI: 10.1039/d2an01985j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Microfluidic technologies have proven to be a reliable tool in profiling dynamic insulin secretion from islets of Langerhans. Most of these systems rely on external pressure sources to induce flow, leading to difficulties moving to more elaborate systems. To reduce complexity, a microfluidic system was developed that used a single vacuum source at the outlet to drive fluidic transport of immunoassay reagents and stimulation solutions throughout the device. A downside to this approach is the lack of flow control over the reagents delivered to the islet chamber. To address this challenge, 4-layer pneumatic valves were integrated into the perfusion lines to automate and control the delivery of stimulants; however, it was found that as the valves closed, spikes in the flow would lead to abnormal insulin secretion profiles. Fluidic capacitors were then incorporated after the valves and found to remove the spikes. The combination of the valves and capacitors resulted in automated collection of insulin secretion profiles from single murine islets that were similar to those previously reported in the literature. In the future, these integrated fluidic components may enable more complex channel designs to be used with a relatively simple flow control solution.
Collapse
Affiliation(s)
- Damilola I Adeoye
- Department of Chemistry & Biochemistry, Florida State University, 95 Chieftain Way, Tallahassee, FL 32306, USA.
| | - Yao Wang
- Department of Chemistry & Biochemistry, Florida State University, 95 Chieftain Way, Tallahassee, FL 32306, USA.
| | - Joshua J Davis
- Department of Chemistry & Biochemistry, Florida State University, 95 Chieftain Way, Tallahassee, FL 32306, USA.
| | - Michael G Roper
- Department of Chemistry & Biochemistry, Florida State University, 95 Chieftain Way, Tallahassee, FL 32306, USA. .,Program in Molecular Biophysics, Florida State University, 95 Chieftain Way, Tallahassee, FL 32306, USA
| |
Collapse
|
6
|
Aubry G, Lee HJ, Lu H. Advances in Microfluidics: Technical Innovations and Applications in Diagnostics and Therapeutics. Anal Chem 2023; 95:444-467. [PMID: 36625114 DOI: 10.1021/acs.analchem.2c04562] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Guillaume Aubry
- School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| | - Hyun Jee Lee
- School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| | - Hang Lu
- School of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States.,Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia 30332, United States
| |
Collapse
|
7
|
Zandi Shafagh R, Youhanna S, Keulen J, Shen JX, Taebnia N, Preiss LC, Klein K, Büttner FA, Bergqvist M, van der Wijngaart W, Lauschke VM. Bioengineered Pancreas-Liver Crosstalk in a Microfluidic Coculture Chip Identifies Human Metabolic Response Signatures in Prediabetic Hyperglycemia. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2022; 9:e2203368. [PMID: 36285680 PMCID: PMC9731722 DOI: 10.1002/advs.202203368] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 10/05/2022] [Indexed: 05/19/2023]
Abstract
Aberrant glucose homeostasis is the most common metabolic disturbance affecting one in ten adults worldwide. Prediabetic hyperglycemia due to dysfunctional interactions between different human tissues, including pancreas and liver, constitutes the largest risk factor for the development of type 2 diabetes. However, this early stage of metabolic disease has received relatively little attention. Microphysiological tissue models that emulate tissue crosstalk offer emerging opportunities to study metabolic interactions. Here, a novel modular multitissue organ-on-a-chip device is presented that allows for integrated and reciprocal communication between different 3D primary human tissue cultures. Precisely controlled heterologous perfusion of each tissue chamber is achieved through a microfluidic single "synthetic heart" pneumatic actuation unit connected to multiple tissue chambers via specific configuration of microchannel resistances. On-chip coculture experiments of organotypic primary human liver spheroids and intact primary human islets demonstrate insulin secretion and hepatic insulin response dynamics at physiological timescales upon glucose challenge. Integration of transcriptomic analyses with promoter motif activity data of 503 transcription factors reveals tissue-specific interacting molecular networks that underlie β-cell stress in prediabetic hyperglycemia. Interestingly, liver and islet cultures show surprising counter-regulation of transcriptional programs, emphasizing the power of microphysiological coculture to elucidate the systems biology of metabolic crosstalk.
Collapse
Affiliation(s)
- Reza Zandi Shafagh
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
- Division of Micro‐ and NanosystemsKTH Royal Institute of TechnologyStockholm10044Sweden
| | - Sonia Youhanna
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
| | - Jibbe Keulen
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
- Division of Micro‐ and NanosystemsKTH Royal Institute of TechnologyStockholm10044Sweden
- Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology70376StuttgartGermany
- University of Tuebingen72074TuebingenGermany
| | - Joanne X. Shen
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
| | - Nayere Taebnia
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
| | - Lena C. Preiss
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
- Department of Drug Metabolism and Pharmacokinetics (DMPK)The Healthcare Business of Merck KGaA64293DarmstadtGermany
| | - Kathrin Klein
- Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology70376StuttgartGermany
- University of Tuebingen72074TuebingenGermany
| | - Florian A. Büttner
- Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology70376StuttgartGermany
- University of Tuebingen72074TuebingenGermany
| | - Mikael Bergqvist
- Division of Micro‐ and NanosystemsKTH Royal Institute of TechnologyStockholm10044Sweden
| | | | - Volker M. Lauschke
- Department of Physiology and PharmacologyKarolinska InstitutetStockholm17711Sweden
- Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology70376StuttgartGermany
- University of Tuebingen72074TuebingenGermany
| |
Collapse
|
8
|
Microfluidic Technology for Evaluating and Preserving Islet Function for Islet Transplant in Type 1 Diabetes. CURRENT TRANSPLANTATION REPORTS 2022. [DOI: 10.1007/s40472-022-00377-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Parent C, Laurent P, Goujon CE, Mermet X, Keiser A, Boizot F, Charles R, Audebert L, Fouillet Y, Cubizolles M. A versatile and automated microfluidic platform for a quantitative magnetic bead based protocol: application to gluten detection. LAB ON A CHIP 2022; 22:3147-3156. [PMID: 35678256 DOI: 10.1039/d2lc00328g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
A microfluidic platform for the integration of multi-step biological assays has been developed. The presented system is a unique instrument compatible with microfluidic chips for various applications based on bead manipulation. Two examples of microfluidic cartridges are presented here. The first one contains two rows of eight chambers (40 and 80 μL), six reagent inlets, eight testing solution (calibrators and samples) inlets and eight outlets to reproduce precisely each step of a biological assay. This configuration is versatile enough to integrate many different biological assays and save a lot of development time. The second architecture is dedicated to one specific protocol and is completely automated from the standard and sample dilutions to the optical detection. Linear dilutions have been integrated to prepare automatically a range of standard concentrations and outlets have been modified for integrated colorimetric detection. The technology uses pneumatically collapsible chambers to perform all the fluidic operations for a fully automated protocol such as volume calibrations, fluid transport, mixing, and washing steps. A programmable instrument with a software interface has been developed to adapt rapidly a protocol to this cartridge. As an example, these new microfluidic cartridges have been used to successfully perform an immunoassay for gluten detection in the dynamic range of 10-30 ppm with good sensitivity (2 ppm) and specificity.
Collapse
Affiliation(s)
- Charlotte Parent
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | - Patricia Laurent
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | | | - Xavier Mermet
- CEA, LETI, Technologies for Healthcare and Biology Division, Univ. Grenoble Alpes, LSIV, F-38000 Grenoble, France
| | - Armelle Keiser
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | - François Boizot
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | - Raymond Charles
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | - Lucas Audebert
- CEA, LETI, Technologies for Healthcare and Biology Division, Univ. Grenoble Alpes, LS2P, F-38000 Grenoble, France
| | - Yves Fouillet
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| | - Myriam Cubizolles
- CEA, LETI, Technologies for Healthcare and Biology Division, Microfluidic Systems and Bioengineering Lab, Univ. Grenoble Alpes, F-38000 Grenoble, France.
| |
Collapse
|